Molecular evidence for the existence of CML-specific T cell responses was brought forward by Cheever et al who demonstrated that CD4 T cell immunity could be generated toward BCR-ABL expressing cell lines after vaccination of mice with peptides generated from the junctional region of the BCR-ABL fusion protein [16]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.